Lois Groden

Whilst the pandemic has caused unprecedented disruption on research and clinical trials, it has also launched the clinical trial landscape into a new area, one with the enhanced utilisation of decentralised trials and the long-awaited embracement of digital technologies to deliver improved patient care, reduced clinical trial costs and speedier outcomes. We have also seen […]

M&A and valuations in the CRO sector – March 2021 The level of impact that Covid-19 has had on M&A activity is comparable to that of the Great Financial Crisis, however, the rebound has been notably stronger. In the last year c.70 deals completed with a significant contribution from the second half of the year. […]

The impact of COVID-19 on M&A and valuations in the CRO sectorUnsurprisingly, the CRO market, like many other sectors has been impacted markedly by the global pandemic. Global trials have been suspended as patient recruitment has become strained and operating sites closed. Pharma sponsors have begun to rethink how to adapt the drug development paradigm […]